Semaglutide

Description

Semaglutide: Overview and Dosage

Description:
Semaglutide is a synthetic analogue of the human incretin hormone glucagon-like peptide-1 (GLP-1), which is designed to aid in the management of blood sugar levels and promote weight loss. Its mechanism of action involves stimulating insulin secretion, enhancing glucose clearance from the bloodstream, and aiding in glycemic control. Moreover, it influences neural pathways related to hunger and satiety, making it a valuable asset for both diabetes treatment and obesity management.

Indications:
– Blood Sugar Control: Effective in lowering blood glucose levels for individuals with type 2 diabetes.
– Weight Loss: Promotes significant weight reduction, with patients experiencing losses up to 20% of their initial body weight, a feat previously achieved only through bariatric surgery.

Pharmacological Actions:
– Increases insulin secretion while reducing glucagon production, thus preventing hypoglycemic episodes.
– Prolongs the lifespan of beta cells within the pancreas.
– Slows gastric emptying, enhancing the sensation of fullness.
– Alters brain activity in areas responsible for appetite regulation and food reward, thus reducing cravings for high-fat foods.

Dosage:
– Starting Dose: Initial administration typically begins at 0.25 mg per week.
– Incremental Increase: The dosage may be gradually increased based on individual response and tolerance, with a maximum recommended dose reaching 2.5 mg per week.
– Administration: The medication is often reconstituted with bacteriostatic water before injection.

Storage Guidelines:
– Freeze-Dried (Unmixed):
– Short-term Storage: Stable at room temperature for several months but preferably refrigerated upon receipt to maximize stability and longevity (1-2 years).
– Long-term Storage: For extended non-use, store in a freezer at -18°C (0°F), in which case stability can last 2-3 years.

• Reconstituted (Mixed):
• Once reconstituted, peptide solutions are generally stable for up to 30 days when stored in the refrigerator, though stability may vary depending on the peptide’s sequence and inherent factors.

Important Note:
Due to regulatory and licensing constraints, specific guidance regarding the administration or research use of Semaglutide is not provided. It is advisable to consult a healthcare professional or research guidelines for appropriate usage protocols.

1. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.

2. Baekdal, TA, Thomsen, M, & Kuhre, RE et al. Investigation of the effect of semaglutide on postprandial plasma glucose excursions in T2DM subjects on metformin. Endocrine Connections. 2021;10(1), 24-32.

3. O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649.

4. Müller TD, Finan B, Bloom SR, et al. Glucagon-like Peptide 1 (GLP-1). Endocrine Reviews. 2019; 40(3), 866–934.

5. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-88.

6. Schmidt JB, Gregersen NT, Pedersen SD, et al